Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

Background The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) >= 20 but <45 mL/min/1.73 m(2) or an eGFR >= 45 but <90 mL/min/1.73 m(2) with a urinary albumin:creatinine ratio (uACR) >= 200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected. Results Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m(2) (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m(2). The median uACR was 412 mg/g) (quartile 1-quartile 3 94-1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)]. Conclusions EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.

Automated summary

The EMPA-KIDNEY trial aims to evaluate the effects of empagliflozin on the risk of kidney disease progression or cardiovascular death in patients with chronic kidney disease. The trial includes a widely generalizable population of CKD patients and uses a streamlined design with minimal data collection. Results are anticipated in 2022.